CL2015001802A1 - Compuestos derivados de quinolonas; composicion farmaceutica; y uso para el tratamiento de enfermedaddes mediadas por la inhibicion de hif polilhidrolasa, tal como infarto al miocardio, accidente cerebrovascular, anemia, entre otros - Google Patents
Compuestos derivados de quinolonas; composicion farmaceutica; y uso para el tratamiento de enfermedaddes mediadas por la inhibicion de hif polilhidrolasa, tal como infarto al miocardio, accidente cerebrovascular, anemia, entre otrosInfo
- Publication number
- CL2015001802A1 CL2015001802A1 CL2015001802A CL2015001802A CL2015001802A1 CL 2015001802 A1 CL2015001802 A1 CL 2015001802A1 CL 2015001802 A CL2015001802 A CL 2015001802A CL 2015001802 A CL2015001802 A CL 2015001802A CL 2015001802 A1 CL2015001802 A1 CL 2015001802A1
- Authority
- CL
- Chile
- Prior art keywords
- polyhydrolase
- hif
- quinolones
- anemia
- inhibition
- Prior art date
Links
- 208000006011 Stroke Diseases 0.000 title 1
- 208000007502 anemia Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 208000010125 myocardial infarction Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000007660 quinolones Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3600MU2012 | 2012-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015001802A1 true CL2015001802A1 (es) | 2015-10-02 |
Family
ID=54148255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015001802A CL2015001802A1 (es) | 2012-12-24 | 2015-06-22 | Compuestos derivados de quinolonas; composicion farmaceutica; y uso para el tratamiento de enfermedaddes mediadas por la inhibicion de hif polilhidrolasa, tal como infarto al miocardio, accidente cerebrovascular, anemia, entre otros |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9394300B2 (OSRAM) |
| EP (1) | EP2935221B1 (OSRAM) |
| JP (1) | JP6026013B2 (OSRAM) |
| KR (1) | KR101733901B1 (OSRAM) |
| CN (1) | CN104903295B (OSRAM) |
| AP (1) | AP2015008502A0 (OSRAM) |
| AR (1) | AR094300A1 (OSRAM) |
| AU (1) | AU2013368843B2 (OSRAM) |
| BR (1) | BR112015014222B1 (OSRAM) |
| CA (1) | CA2894636C (OSRAM) |
| CL (1) | CL2015001802A1 (OSRAM) |
| EA (1) | EA028402B1 (OSRAM) |
| ES (1) | ES2660288T3 (OSRAM) |
| IL (1) | IL239109B (OSRAM) |
| JO (1) | JO3781B1 (OSRAM) |
| MA (1) | MA38138A1 (OSRAM) |
| MX (1) | MX373392B (OSRAM) |
| MY (1) | MY175854A (OSRAM) |
| NZ (1) | NZ708605A (OSRAM) |
| PH (1) | PH12015501452B1 (OSRAM) |
| SG (1) | SG11201504458XA (OSRAM) |
| TR (1) | TR201802305T4 (OSRAM) |
| TW (1) | TWI598339B (OSRAM) |
| UA (1) | UA117122C2 (OSRAM) |
| WO (1) | WO2014102818A1 (OSRAM) |
| ZA (1) | ZA201503814B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016034108A1 (zh) * | 2014-09-02 | 2016-03-10 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其应用 |
| WO2016045125A1 (en) * | 2014-09-28 | 2016-03-31 | Merck Sharp & Dohme Corp. | Inhibitors of hif prolyl hydroxylase |
| CL2015003047A1 (es) * | 2015-10-15 | 2016-06-17 | Univ Chile | Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CN108069957B (zh) * | 2016-11-09 | 2022-11-04 | 广东东阳光药业有限公司 | 脯氨酰羟化酶抑制剂及其用途 |
| CN113004271A (zh) | 2017-05-09 | 2021-06-22 | 杭州安道药业有限公司 | 吲哚嗪衍生物及其在医药上的应用 |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| WO2021181360A1 (en) * | 2020-03-13 | 2021-09-16 | Cadila Healthcare Limited | Novel salts of quinolone compounds |
| US20230190731A1 (en) * | 2020-03-17 | 2023-06-22 | Zydus Lifesciences Limited | Formulation comprising hif prolyl hydroxylase inhibitors |
| US20230218592A1 (en) | 2020-04-20 | 2023-07-13 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| CN115666539A (zh) * | 2020-05-29 | 2023-01-31 | 兹杜斯生命科学有限公司 | 银屑病和皮肤炎性疾病的治疗 |
| WO2021245533A1 (en) * | 2020-06-01 | 2021-12-09 | Cadila Healthcare Limited | Treatment for the inflammatory bowel disease |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| BR112023016770A2 (pt) * | 2021-03-19 | 2023-10-03 | Zydus Lifesciences Ltd | Forma cristalina de um composto, processo para a preparação de uma forma cristalina de um composto, processo para a preparação de um composto, composto, composição compreendendo um composto e composição farmacêutica |
| BR112023018949A2 (pt) * | 2021-03-19 | 2023-10-17 | Zydus Lifesciences Ltd | Composto, uso do mesmo para tratar anemia falciforme e composição farmacêutica compreendendo o referido composto |
| WO2022238745A1 (en) * | 2021-05-14 | 2022-11-17 | Zydus Lifesciences Limited | Topical pharmaceutical composition of hif prolyl hydroxylase inhibitors |
| TW202313072A (zh) | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | 檸檬酸鐵之兒科調配物 |
| CN113549011B (zh) * | 2021-08-10 | 2023-05-09 | 广东东阳光药业有限公司 | 德度司他的共晶或盐及其制备方法和用途 |
| CN117836275A (zh) * | 2021-09-20 | 2024-04-05 | 载度思生命科学有限公司 | 德度司他颗粒及其组合物 |
| CN119486735A (zh) * | 2022-06-24 | 2025-02-18 | 载度思生命科学有限公司 | 用于肾小球疾病的治疗 |
| WO2024028744A1 (en) * | 2022-08-01 | 2024-02-08 | Zydus Lifesciences Limited | Treatment for aplastic anemia (aa) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2138929A1 (en) | 1993-12-30 | 1995-07-01 | Klaus Weidmann | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
| CN102718708A (zh) | 2003-06-06 | 2012-10-10 | 菲布罗根有限公司 | 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途 |
| JP4792048B2 (ja) * | 2005-03-02 | 2011-10-12 | ファイブロゲン インコーポレイティッド | チエノピリジン化合物およびその使用方法 |
| WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| AU2006326662B2 (en) * | 2005-12-09 | 2011-07-28 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof |
| TW200808793A (en) * | 2006-03-07 | 2008-02-16 | Smithkline Beecham Corp | Prolyl hydroxylase inhibitors |
| AU2007234408B2 (en) * | 2006-04-04 | 2011-05-19 | Fibrogen, Inc. | Pyrrolo- and thiazolo-pyridine compounds as HIF modulators |
| JP2009537558A (ja) * | 2006-05-16 | 2009-10-29 | スミスクライン・ビーチャム・コーポレイション | プロリルヒドロキシラーゼ阻害剤 |
| US20100056516A1 (en) * | 2006-07-17 | 2010-03-04 | Williams Peter D | 1-hydroxy naphthyridine compounds as anti-hiv agents |
| ES2393326T3 (es) | 2006-12-18 | 2012-12-20 | Amgen, Inc | Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos |
| CA2683956C (en) * | 2007-04-18 | 2012-12-18 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| CN101663037A (zh) * | 2007-04-18 | 2010-03-03 | 默克公司 | 新的1,8-二氮杂萘化合物 |
| AU2008248165B2 (en) * | 2007-05-04 | 2011-12-08 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
| EP2150251B9 (en) * | 2007-05-04 | 2013-02-27 | Amgen, Inc | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| WO2008138060A1 (en) | 2007-05-16 | 2008-11-20 | Cowper Norman T | System and method for maximising solids concentration of slurry pumped through a pipeline |
| CN101932324A (zh) * | 2007-11-30 | 2010-12-29 | 葛兰素史密斯克莱有限责任公司 | 脯氨酰羟化酶抑制剂 |
| US8471024B2 (en) * | 2008-02-25 | 2013-06-25 | Merck Sharp & Dohme, Corp. | Tetrahydrofuropyridones |
| EP2257171B1 (en) * | 2008-02-25 | 2016-02-10 | Merck Sharp & Dohme Corp. | Tetrahydro-1h-pyrrolo-fused pyridones |
| CN101951775A (zh) * | 2008-02-25 | 2011-01-19 | 默沙东公司 | 四氢噻吩并吡啶 |
| JP2011525924A (ja) * | 2008-06-25 | 2011-09-29 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| HRP20140705T1 (hr) | 2009-07-17 | 2014-09-12 | Japan Tobacco, Inc. | Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina |
| AR077892A1 (es) * | 2009-08-20 | 2011-09-28 | Vifor Int Ag | Quinolinas antagonistas de la hepcidina |
| CN103608346B (zh) | 2011-02-02 | 2016-06-15 | 菲布罗根有限公司 | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 |
| WO2013043621A1 (en) | 2011-09-23 | 2013-03-28 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| WO2013115265A1 (ja) * | 2012-01-31 | 2013-08-08 | 富山化学工業株式会社 | 抗ｈｉｖ活性を有する複素環化合物 |
-
2013
- 2013-12-23 TR TR2018/02305T patent/TR201802305T4/tr unknown
- 2013-12-23 UA UAA201506784A patent/UA117122C2/uk unknown
- 2013-12-23 BR BR112015014222-2A patent/BR112015014222B1/pt active IP Right Grant
- 2013-12-23 KR KR1020157016080A patent/KR101733901B1/ko active Active
- 2013-12-23 CA CA2894636A patent/CA2894636C/en active Active
- 2013-12-23 MY MYPI2015001457A patent/MY175854A/en unknown
- 2013-12-23 SG SG11201504458XA patent/SG11201504458XA/en unknown
- 2013-12-23 MX MX2015008233A patent/MX373392B/es active IP Right Grant
- 2013-12-23 CN CN201380067856.4A patent/CN104903295B/zh active Active
- 2013-12-23 AP AP2015008502A patent/AP2015008502A0/xx unknown
- 2013-12-23 TW TW102147766A patent/TWI598339B/zh active
- 2013-12-23 JP JP2015548889A patent/JP6026013B2/ja active Active
- 2013-12-23 AU AU2013368843A patent/AU2013368843B2/en active Active
- 2013-12-23 NZ NZ708605A patent/NZ708605A/en unknown
- 2013-12-23 ES ES13828997.0T patent/ES2660288T3/es active Active
- 2013-12-23 WO PCT/IN2013/000796 patent/WO2014102818A1/en not_active Ceased
- 2013-12-23 EP EP13828997.0A patent/EP2935221B1/en active Active
- 2013-12-23 US US14/652,024 patent/US9394300B2/en active Active
- 2013-12-23 EA EA201591195A patent/EA028402B1/ru not_active IP Right Cessation
- 2013-12-23 JO JOP/2013/0383A patent/JO3781B1/ar active
- 2013-12-27 AR ARP130105055A patent/AR094300A1/es active IP Right Grant
-
2015
- 2015-05-27 ZA ZA2015/03814A patent/ZA201503814B/en unknown
- 2015-05-29 MA MA38138A patent/MA38138A1/fr unknown
- 2015-06-01 IL IL239109A patent/IL239109B/en active IP Right Grant
- 2015-06-22 CL CL2015001802A patent/CL2015001802A1/es unknown
- 2015-06-23 PH PH12015501452A patent/PH12015501452B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015001802A1 (es) | Compuestos derivados de quinolonas; composicion farmaceutica; y uso para el tratamiento de enfermedaddes mediadas por la inhibicion de hif polilhidrolasa, tal como infarto al miocardio, accidente cerebrovascular, anemia, entre otros | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
| CO7071129A2 (es) | Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CO6960541A2 (es) | Nueva composición farmacéutica resistente al abuso para el tratamiento de la dependencia de opioides | |
| CL2014001855A1 (es) | Compuestos derivados de imidazopirrolidinona o sus sales, formas cristalinas; composicion farmaceutica que los comprende; y su uso para el tratamiento de un trastorno o enfermedad mediada por la actividad de mdm2 y/o mdm4 tales como enfermedades proliferativas, especialmente cancer. | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| CL2015001731A1 (es) | Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras. | |
| CL2015001724A1 (es) | Compuestos derivados de péptidos, agonistas de oxitocina; composicion farmaceutica; y su uso para en el tratamiento del autismo, estres, ansiedad, depresion, esquizofrenia,entre otros. | |
| CL2014002334A1 (es) | Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras. | |
| CL2014001858A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer. | |
| LT2916860T (lt) | Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą | |
| CL2015000482A1 (es) | Compuestos derivado de 6-aminoacido-heteriarildihidropirimidinas; proceso de obtención; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la infección por el virus de la hepatitis b | |
| CL2014001065A1 (es) | Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer. | |
| CL2014002919A1 (es) | Compuestos derivados de 1h-indol-4-il-metil-(heterociclo benzofusionado); composicion y combinacion farmaceutica; y uso en el tratamiento de un trastorno mediado por la activacion del complemento o la ruta alternativa del mismo. | |
| CL2014002301A1 (es) | Compuestos derivados de pirimidin piridinas sustituidas, inhibidores de serina/treonina cinasas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento de una enfermedad hiperproliferativa tal como melanoma, cancer, leucemias y una enfermedad inflamatoria como artritis y reumatismo entre otras. | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| CL2015001014A1 (es) | Composicion de silicato de zirconio microporoso, util para el tratamiento de la hipercalemia | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| EP2845602A4 (en) | CYCLOSPORINE-CONTAINING NON-REFRESHING OPHTHALMIC NANOEMULSION COMPOSITION | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
| CL2014001772A1 (es) | Compuestos derivados de (furano/pirano)-[2,3, b]piridin-amida, antagonistas del receptor p2x7; composicion farmaceutica; y su uso para el tratamiento del dolor, enfermedades neurodegenerativas, neuroinflamatorias, entre otras. | |
| LT2939665T (lt) | Farmacinė kompozicija, skirta živ infekcijų gydymui |